Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC
In non-small cell lung cancer (NSCLC), the most prevalent driver mutations in epidermal growth factor receptor (_EGFR_) are deletions in exon 19 (Ex19del) and L858R mutations in exon 21, which comprise approximately 90% of all _EGFR_ mutations. In contrast, exon 20 insertion (Ex20ins) mutations are...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.21.154 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|